ReviewCellular and molecular life sciences : CMLS2016
Neurotrophin signaling in cancer stem cells.
Review in Cellular and molecular life sciences : CMLS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Meta-analysis of gene signatures and key pathways indicates suppression of JNK pathway as a regulator of chemo-resistance in AML.Scientific reports · 2021Pooled it
- Hallmarks of epithelial-mesenchymal plasticity in cancer.Molecular cancer · 2026Review
- TrkA activation sustains chemotherapy resistance in chemotolerant medulloblastoma cells.Acta neuropathologica communications · 2026Article
- The role of miRNAs in the development of brain metastases originating from lung adenocarcinoma.Frontiers in genetics · 2026Article
- Macrophages in endometriosis: key roles and emerging therapeutic opportunities-a narrative review.Reproductive biology and endocrinology : RB&E · 2025Review
- ERCC1/NGFR affects prognosis in basal-like breast cancer.European journal of medical research · 2025Article
- An integrative analysis combining bioinformatics, network pharmacology and experimental methods identified key genes of EGCG targets in Nasopharyngeal Carcinoma.Discover oncology · 2025Article
- Hijacking of the nervous system in cancer: mechanism and therapeutic targets.Molecular cancer · 2025Review
- The neuro-immune axis in cancer: mechanisms of innervation-driven tumor progression and therapeutic opportunities.Frontiers in immunology · 2025Review
- Article
- Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy.Journal of experimental & clinical cancer research : CR · 2024Article
- Nerve Growth Factor and the Role of Inflammation in Tumor Development.Current issues in molecular biology · 2024Review
- Distribution of Nerve Fibers in Abdominal Wall Endometriosis and Their Clinical Significance.Journal of pain research · 2024Article
- Periampullary cancer and neurological interactions: current understanding and future research directions.Frontiers in oncology · 2024Review
- Nerve Growth Factor and Autoimmune Diseases.Current issues in molecular biology · 2023Review
- Effect of ZEB1 Associated with microRNAs on Tumor Stem Cells in Head and Neck Cancer.International journal of molecular sciences · 2023Article
- Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson's disease.Frontiers in immunology · 2023Article
- Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.Frontiers in immunology · 2022Article
- Identification and validation of neurotrophic factor-related genes signature in HNSCC to predict survival and immune landscapes.Frontiers in genetics · 2022Article
- Brain derived neurotrophic factor declines after complete curative resection in gastrointestinal cancer.PeerJ · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs), are thought to be at the origin of tumor development and resistance to therapies. Thus, a better understanding of the molecular mechanisms involved in the control of CSC stemness is essential to the design of more effective therapies for cancer patients. Cancer cell stemness and the subsequent expansion of CSCs are regulated by micro-environmental signals including neurotrophins. Over the years, the roles of neurotrophins in tumor development have been well established and regularly reviewed. Especially, nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) are reported to stimulate tumor cell proliferation, survival, migration and/or invasion, and favors tumor angiogenesis. More recently, neurotrophins have been reported to regulate CSCs. This review briefly presents neurotrophins and their receptors, summarizes their roles in different cancers, and discusses the emerging evidence of neurotrophins-induced enrichment of CSCs as well as the involved signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.